|Bid||1,080.00 x 0|
|Ask||1,088.00 x 0|
|Day's range||1,058.00 - 1,116.00|
|52-week range||13.15 - 1,276.00|
|Beta (5Y monthly)||-3.03|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Since Novacyt shares have pulled back, a number of top-level directors have purchased stock. This suggests these insiders are confident, but am I? The post Novacyt shares: insiders are buying. Should I buy too? appeared first on The Motley Fool UK.
The UK’s second largest direct-to-consumer investment platform, interactive investor, said it experienced a “record-breaking” day on Monday after news of Pfizer’s COVID-19 vaccine breakthrough sent markets on a tear, the company said in a statement on Tuesday.
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test on Thursday to differentiate between COVID-19 and common winter diseases. Novacyt said its "Winterplex" test panel included two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV). "We believe Winterplex™ is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases," Novacyt CEO Graham Mullis said.